Tsumura (TSE:4540) Stock Cheapens As Profit Strength Meets Quality Questions

Tsumura has been trading like a steady value stock, with the share price roughly flat over the past month and only a small pullback over the past week. Today's Q1 2027 earnings release puts the focus squarely on profit quality. Basic earnings per share came in at ¥86.62 and net income reached ¥6,457 million, while the trailing price tag still sits on a P/E of 9.3x. The real story investors now need to weigh is whether this earnings power and margin profile justify a stock that screens as cheap on paper.

Love Tsumura's low 9.3x P/E but concerned this apparent value might be masking quality issues in the earnings profile? Benchmark it against a curated list of stocks that pair reasonable valuations with stronger fundamentals through our 18 high quality undervalued stocks.

Q1 2027 Earnings Summary

• Revenue, Q1 2027 vs. Q1 2026: ¥49,704 million vs. ¥43,094 million (up about 15.4%)
• Net Income, Q1 2027 vs. Q1 2026: ¥6,457 million vs. ¥4,367 million (up about 47.8%)
• Basic EPS, Q1 2027 vs. Q1 2026: ¥86.62 vs. ¥58.15 (up about 48.9%)
• Trailing 12 Month Basic EPS, Q1 2027 vs. Q1 2026: ¥405.00 vs. ¥338.33 (up about 19.7%)

Prefer clear charts instead of another wall of earnings tables and raw figures? Get a full visual snapshot of Tsumura, with its valuation front and center, in the company report for Tsumura.

Tsumura earnings trend supports defensive appeal

Tsumura looks directionally aligned with a steady, defensive healthcare story. Revenue and net income are higher year on year in Q1 2027, and basic EPS has moved in the same direction. Trailing 12 month EPS is also higher than a year earlier, which backs the idea of a business with reasonably consistent earnings power. The recent consolidation of the Chinese herbal medicine subsidiary points to tighter control over that operation. For investors who see Tsumura as a heritage healthcare stock with relatively resilient demand, this set of numbers broadly supports that view.

Risks to the Tsumura thesis still matter

Even with healthier earnings, Tsumura is not risk free. The stock has slipped about 1% over the past week and is roughly flat over one month, which shows the market is not treating this as a straightforward growth story. Integration of the Shanghai Hongqiao subsidiary can also bring execution and regulatory challenges in China. For anyone worried about pressure from guidelines, reimbursement or competition from Western drugs and other herbal products, these results soften some immediate concerns but do not remove them.

Scan Tsumura's cash flow coverage and subsidiary integration risks in context, then review the full risk analysis for Tsumura which shows 1 important warning sign

Own Your Next Investing Move

If Tsumura's steady earnings profile and low 9.3x P/E have you interested but cautious, register for free with Simply Wall St and add it to a Watchlist to track the share price against fair value and watch how the thesis evolves before deciding on an entry point. Once you decide to take a position, keep on top of what truly matters with the Portfolio Command Center that cuts through noise and highlights key developments affecting your holdings. For a longer term view, use the Community to see how other investors are thinking about Tsumura and similar stocks. This combination helps you spot hidden catalysts and emerging risks early so you can stay a step ahead of the market.

Seeking Alternatives Beyond Tsumura Now

Fresh stock ideas can move fast once momentum builds and early buyers spot a potential breakout. Scan what is still under the radar for now and get in early.

• Spot cash rich compounders before they start flying by scanning a curated list of solid balance sheet and fundamentals stocks (40 results) that filters for financial strength while it still matters.
• Target consistent income streams that can steady a dropping portfolio by reviewing a hand picked set of 43 dividend fortresses built to prioritise resilience first.
• Ride long term demand for electrification trends by assessing a focused group of 8 top copper producer stocks that could benefit if infrastructure spending gains fresh momentum.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com